In classical hodgkin's lymphoma patients with a postive PET after 2 cycles, are you routinely transitioning to escalated BEACOPP?  

Based on the study by Johnson Et al. NEJM 2016 that would be an appropriate action and a strategy that most academic centers undertook prior to the Echelon 1 study.   This early in the treatment algorithm to consider either agent although you could consider the combination based on the recent ...

It is our recomendation for patients with a positive PET ( Deauville score 4, 5) after 2 cycles of ABVD to esclate to BEACOPP. This as @Tycel J. Phillips mentioned based on RATHEL ( Johnson P, et al. New Engl J Med. Press OW, et al. J Clin Oncol. 2016 ).  This strategy produces a 65% long ...

I think there is clear evidence that a positive pet on therapy ( Deauville score 4, 5) predicts for poor outcome with no evidence that further therapy mitigated that , Gallamini A, et al. J Clin Oncol. 2007. Gallamini A, et al. Haematologica. 2014 and Zinzani PL, et al. Eur J Nucl Med Mol Imaging. 2...

Could i ask my learned physicians , is there any formal randomized data in these adaptive studies showing a better outcome with dose escalated and more toxic therapy , specifically in the PET2 postive patients. I interpret these studies as helping  to indentify those patients we can deintensif...